Key Highlights

  • EVMN shares are down 9.79% to $11.80 in pre-market trading.
  • The company announced that its Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis did not meet its primary endpoint.
  • The trial enrolled 121 adults and failed to meet primary and secondary endpoints across all doses studied.
  • The company does not plan to advance EVO756 in atopic dermatitis, though it will continue to evaluate the drug in a separate Phase 2b trial for migraine prophylaxis.
  • The company's lead atopic dermatitis program now shifts to EVO301, which recently generated positive Phase 2a proof-of-concept data, with a Phase 2b trial planned for mid-2027.

Shares Fall on a Failed Dermatitis Trial

Evommune (NYSE:EVMN) shares are falling sharply in pre-market trading after the company announced topline results from its Phase 2b trial evaluating EVO756 in adults with moderate-to-severe atopic dermatitis, which did not meet its primary endpoint of percent change in Eczema Area and Severity index score from baseline at Week 12. Evommune is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases.

The trial enrolled 121 adults over a 12-week treatment period and failed to meet both primary and secondary endpoints across all doses studied, though EVO756 was reported as generally well tolerated with a safety profile consistent with prior studies.

Company Will Not Advance the Drug in This Indication

Based on these results, the company does not plan to advance EVO756 in atopic dermatitis. EVO756 is a first-in-class oral small molecule antagonist of the MRGPRX2 receptor, predominantly found on mast cells and peripheral sensory neurons, and will continue to be evaluated in a separate ongoing Phase 2b trial for migraine prophylaxis, where its safety profile supports continued development.

Pipeline Focus Shifts to a Different Lead Candidate

The company's lead atopic dermatitis program now shifts to EVO301, a long-acting injectable IL-18BP fusion protein that recently generated positive Phase 2a proof-of-concept data. A Phase 2b trial of EVO301 in atopic dermatitis is planned for mid-2027, giving investors a new near-term catalyst to watch in this indication.

Balance Sheet Provides Runway Through the Transition

Evommune maintains a cash runway into 2029, providing financial flexibility as the company redirects its atopic dermatitis strategy toward EVO301 while continuing to advance EVO756 in migraine prophylaxis. Continued progress on both programs will likely shape sentiment in the stock over the coming quarters.